The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.

about

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.

Item

http://www.wikidata.org/entity/Q40086558

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.

@en

type

Item

label

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.

@en

prefLabel

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.

@en

P1476

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.

@en

P2093

Akira Kawashima

http://www.w3.org/2001/XMLSchema#string

Hideyuki Tamai

http://www.w3.org/2001/XMLSchema#string

Jun Kato

http://www.w3.org/2001/XMLSchema#string

Kosaku Moribata

http://www.w3.org/2001/XMLSchema#string

Masayuki Kitano

http://www.w3.org/2001/XMLSchema#string

Mikitaka Iguchi

http://www.w3.org/2001/XMLSchema#string

Naoki Shingaki

http://www.w3.org/2001/XMLSchema#string

Ryo Shimizu

http://www.w3.org/2001/XMLSchema#string

Shinya Taki

http://www.w3.org/2001/XMLSchema#string

Taisei Nakao

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks.

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan

Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.

Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.

Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.

Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.

P304

86-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5009/GNL17048

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28798288

http://www.w3.org/2001/XMLSchema#string

P932

5753689

http://www.w3.org/2001/XMLSchema#string